CEL-SCI Corp: Company Report
8229 Boone Boulevard
Suite 802
Vienna VA 22182
http://www.cel-sci.com/ - Phone: 703-5069460
- Fax: 703-5069471
- Industry : Biotechnology
- Employees : 30
- Exchange : AMEX
CEL-SCI Corporation, is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted, it is the cancer immunotherapy that both kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. Multikine is a type of immunotherapy in that it is immunotherapy, incorporating both active and passive immune activity.
| Stock Activity |
|---|
|
Last Price |
1.21 |
|
52 Week High |
2.10 |
|
52 Week Low |
0.14 |
|
Volume |
3.15 Mil |
|
Average Daily Volume (13wk) |
12.07 Mil |
|
50 Day Moving Average |
1.40 |
|
200 Day Moving Average |
0.63 |
|
Volatility (beta) |
2.29 |
| Stock Price History |
|---|
| | Change | Relative Strength |
|---|
|
Last 3 Months |
154.6% |
99 |
|
Last 6 Months |
334.5% |
99 |
|
Last 12 Months |
581.5% |
98 |
Historical charts
| Institutional Statistics |
|---|
| Analyst Consensus | NA | | fyi | Institutional Ownership | 2.40% |
More Analyst Ratings
Want to learn how to evaluate a stock? Walk through the steps using the Research Wizard. | advertisement
| Financials |
|---|
| | Last 12 Months | 5 Year Growth |
|---|
|
Sales |
50,000.0 |
-56.4% |
|
Income |
-11.1 Mil |
NA |
|
Dividend Rate |
0.00 |
NA |
|
Dividend Yield |
0.00% |
0.00% |
More financials
| Fundamental Data |
|---|
| Debt/Equity Ratio | 0.48 | | Gross Margin | NA | | Net Profit Margin | NA | | Total Shares Outstanding | 149.5 Mil | | Market Capitalization | 180.96 Mil | | Earnings/Share | -0.09 |
More financial ratios
No earnings estimates data available.
|
Recent News